Our data show that PXS-5505 has the potential to increase efficacy of gemcitabine against newly forming and established metastatic disease, demonstrating, in a model of established metastatic disease in pancreatic cancer, that a small-molecule pan-lysyl oxidase inhibitor can potentiate chemotherapy. This evidence concerns the gene LOX and metastatic neoplasm.